Atomoxetine for the Treatment of Cannabis Dependence
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this small open-label trial is to evaluate the feasibility of recruiting
cannabis dependent patients for treatment with Atomoxetine and MIT. The clinical data to date
on Atomoxetine has been limited to children and adults with attention deficit disorder
without co-morbid substance dependence. However, one study estimated that adults with
attention deficit disorder have rates of drug abuse three to four times higher than controls
(Mannuzza S 1998). The study also reported that cannabis and cocaine are most frequently
abused in this population.